MedPath

BLINCYTO

BLINCYTO

Approved
DIN Number

02450283

Drug Class

Human

Market Date

Mar 17, 2016

Company
HC

Amgen Canada Inc

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02450283
AIG Number0157670001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription ,  Schedule D
A
ATC Code
L01FX07 BLINATUMOMAB
Product Specifications
Dosage FormPowder For Solution
Route of AdministrationIntravenous
AHFS Classification10:00.00
Health Canada Classification

ACTIVE INGREDIENTS (1)

BLINATUMOMABActive
Strength: 38.5 MCG / VIAL
Monograph: BLINATUMOMAB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.